Analyst consensus rating
First Tracks Biotherapeutics Analyst Rating: Strong Buy
TRAX is rated Strong Buy by 9 analysts with a $69.44 target. As of 2026-08-20.
Direct answer
First Tracks Biotherapeutics's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $69.44.
Forecast evidence checked August 20, 2026.
Get free First Tracks Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $43.72
- Average price target
- $69.44
- High price target
- $95.00
- Low price target
- $55.00
- Low target gap
- +25.8%
- Target upside
- +58.8%
- High target gap
- +117.3%
- Target range width
- 91.5%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- August 20, 2026
- Valid through
- August 27, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for First Tracks Biotherapeutics?
First Tracks Biotherapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $69.44.
How far are First Tracks Biotherapeutics's low and high targets from the recorded price?
The low target implies +25.8%, while the high target implies +117.3%.
How many analysts are included in First Tracks Biotherapeutics's consensus?
The verified consensus includes 9 analysts.
How is First Tracks Biotherapeutics's target upside or downside calculated?
The average target of $69.44 is divided by the recorded price of $43.72, then one is subtracted to produce +58.8%. This does not guarantee a future return.
When was First Tracks Biotherapeutics's analyst forecast verified?
The data was verified on 2026-08-20. The dataset is valid through 2026-08-27.